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Background: To evaluate the treatment efficacy of a mandibular advancement intraoral appliance (MOA) for treat-
ment of obstructive sleep apnea syndrome (OSAS) in pediatric patients. 
Material and Methods: Eighteen patients (mean=8.39 years old, women=44.4%) were selected. Sleep disorders, 
sleep bruxism, and temporomandibular disorders were assessed by the Sleep Disturbance Scale for Children 
(SDSC), the BiteStrip® (portable SB device), and the Research Diagnostic Criteria for Temporomandibular Dis-
orders, respectively. The clinical diagnosis of OSAS was confirmed with a type 3 portable monitor device (Ap-
neaLinkTM Plus). A silicon-based material MOA was used by patients for 60 days, and the results were compared 
to baseline. 
Results: The median RDI was significantly reduced from 10 to 4.5 events/hour. Nadir SpO2 significantly in-
creased from 82.6% to 88.9%. Total snoring events/hour have also significantly decreased from 205.5 to 91.5. 
Signs and symptoms of TMD remained unaltered. There was also a reduction from moderate to absence of SB in 
12 patients. Similarly, all variables measured by the SDSC have had very significant reductions: disorders of ini-
tiating and maintaining sleep, sleep disordered breathing, disorders of arousal, nightmares, sleep wake transition 
disorders, disorders of excessive somnolence, and sleep hyperhidrosis. 
Conclusions: In selected cases, OA maybe considered as an alternative for the OSAS treatment.
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Introduction
Obstructive sleep apnea syndrome (OSAS) is a respira-
tory disorder, common in children, which occurs during 
sleep; characterized by prolonged partial obstruction of 
the upper airway space (hypoventilation) and/or by in-
termittent complete obstruction (apnea). This process 
interrupts both the normal ventilation, and the upper 
airway flow, and the normal sleep patterns (1). The main 
symptoms of OSAS are: snoring, respiratory effort, and 
intense body movements during sleep. These variables 
have serious consequences to children: slowing down 
in normal body growth, and eventual cardiovascular 
complications such as pulmonary hypertension. The 
major risk factors for OSAS are: obesity, craniofacial 
malformations, and neuromuscular diseases. The prev-
alence of childhood snoring, based on clinical history/
examination and structured questionnaires, varies from 
1.5 to 15% (2). The OSAS pathophysiology is multifac-
torial, with many anatomical/functional/neuromuscular 
factors involved. Soft/adipose tissues, musculature, and 
the craniofacial bones will directly affect the configu-
ration and dimension of the pharynx. Consequently, it 
is frequently observed that patients with OSAS pres-
ent with: hypotonic tongue, macroglossy, retrognathic 
mandible/maxilla, micrognathism, V-shaped palate, 
narrow arches, and crossbites (3,4).
Due to its chronic nature, OSAS treatments consist of 
clinical and surgical modalities, depending on its se-
verity. The treatment objectives are both to normalize 
breathing during sleep, and to eradicate daytime sleepi-
ness, and to reduce neuropsychological/cardiovascular 
alterations. It must provide the patient with good quality 
of life without risks or side effects (5,6). The mandibular 
advancement intraoral appliance (MOA) therapy is used 
during sleep with the objective of preventing the col-
lapse between the oropharynx and the tongue base (i.e., 
the upper airway space patency). They are non-invasive, 
comfortable, easily adaptable, and effective devices for 
patients; and they have been a growing line of treat-
ment for the last 20 years (6). The MOA primary mode 
of action is to advance the mandible and to reposition 
the tongue, with the objective of increasing the airway 
space and to facilitate the superior respiratory system 
(7). Pediatric studies using MOA are missing, and there 
are few studies using this appliance during sleep for 
OSAS in this age group (8). 
The primary objective of this study was to evaluate the 
effects of the MOA treatment in children with OSAS. In 
addition, the effects of MOA in sleep bruxism (SB) and 
signs and symptoms of temporomandibular disorders 
(TMD) will also be assessed. 
Material and Methods
-Study design
A before-and-after clinical trial design was carried out 
with the objective to assess the improvement in upper 
airway obstruction after the use of MOA in children 
with OSAS (9).
-Population, inclusion and exclusion criteria, and study 
protocol
Eighteen patients from the Otolaryngology Services at 
the São Lucas Hospital and the Clinical Hospital of Por-
to Alegre, who were in the waiting list for amygdalec-
tomy,  participated in the study.  Patients with clinical 
history of snoring during sleep (minimum 3 episodes/
week), from both sexes, and between the ages of 5 to 12 
were included.
Clinical history of sleep apnea and snoring reported by 
parents, TMD, joint pain, muscle pain, sleep disorders, 
SB, and daily habits were assessed. Regarding general 
health, history of systemic diseases and use of medi-
cation were also verified. In the clinical examination; 
the presence of wearing facets, edentations in the lips, 
tongue and jugal mucosa, and teeth number were also 
evaluated.
The exclusion criteria were patients with: a) relevant 
craniofacial skeletal abnormalities, b) history of orth-
odontic treatment, c) active periodontal disease and/or 
tooth mobility, d) medication use acting in the central 
nervous system (anxiolytics/antidepressants), e) unsta-
ble occlusion (i.e., without maximum intercuspal posi-
tion), and f) presence of TMD spontaneous pain.
The following diagnostic tests and questionnaires were 
used in the OSAS, quality of sleep, SB, and signs and 
symptoms of TMD assessments: a) respiratory distur-
bance index (RDI) and blood oxygen saturation (SpO2) 
using a type 3 portable device (ApneaLinkTM Plus, 
version 9.00, ResMed), d) the Sleep Disturbance Scale 
for Children (SDSC) self-reported by parents, e) the 
portable electromyogram (EMG) device for SB (BiteS-
trip®), and f) the Research Diagnostic Criteria for Tem-
poromandibular Disorders (RDC/TMD) axes I and II 
(Fig. 1). Only in included patients presenting RDI≥1.5 
in the ApneaLinkTM Plus, all above tests were per-
formed before-and-after the 60-day use of the MOA for 
2 months.
-Obstructive sleep apnea evaluation by a portable moni-
toring device and by subjective sleep assessment
In the preliminary diagnosis of OSAS, parents answered 
both the SDSC, and the parents’ reports regarding snor-
ing or any sleep alterations (10). The SDSC evaluates 
children’s sleep patterns of behavior. The SDSC is re-
producible, valid, and with internal consistency; and it 
has the capacity to distinguish common sleep disorders 
among children and adolescents: a) disorders of initiat-
ing and maintaining sleep, b) sleep breathing disorders, 
c) disorders of arousal/nightmares, d) sleep-wake tran-
sition disorders, e) disorders of excessive somnolence, 
and f) sleep hyperhidrosis (11). 
In order to confirm the OSAS diagnosis, these patients 
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Fig. 1. Study diagram describing the research protocol. * Inclusion criteria: 
patients who were in the waiting list for amygdalectomy, with clinical history 
of snoring during sleep (minimum 3 episodes/week), from both sexes, between 
the ages of 5 to 12.
used a portable home cardiorespiratory monitoring 
type 3 device according to the AASM (12,13). This de-
vice (ApneaLinkTM Plus, version 9.00, ResMed) has 4 
monitored channels, including respiratory effort, pulse 
rate, and peripheral oxygen saturation (SpO2) and has 
been validated against polysomnography (14-18). The 
variables measured by the ApneaLinkTM Plus, as rec-
ommended by the AASM, were: a) oxygen desaturation 
index (ODI) calculated from the number of SpO2 drops 
below 3% from baseline saturation, b) RDI calculated 
from the number of obstructive episodes over the total 
recording time, c) snoring events, d) saturation time, e) 
average saturation, f) lowest saturation, and g) registra-
tion time (14).
Patients underwent an initial portable apnea/hypopnea 
appliance evaluation which confirmed the initial clini-
cal diagnosis. Then, only patients presenting RDI≥1.5 
in the ApneaLink™ Plus used the individualized MOA 
for 2 months with the objective of reducing obstruc-
tive events, and underwent another global evaluation 
(before-and-after) (5,19). All procedures were carried 
out by a single experient and trained examiner; and the 
exam interpretation was always performed by the same 
physician, who was a sleep medicine specialist blind 
to the use of the MOA, following the AASM scoring 
guidelines (2012) (14). The cardiovascular registrations 
were performed during the whole night, in non-induced 
sleep, at the patients’ home place.
-Mandibular advancement intraoral appliance manu-
facturing
In order to make the MOA appliance, type IV gipsy 
casts were mounted in a semi-adjustable articulator 
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(Bio-Art Dental Equipments Ltd., São Paulo, Brazil) 
at 70% of the patient’s mandibular maximum protru-
sive movement (8 mm advancement), with a mandibu-
lar opening varying from 5 to 7 mm. Then, two soft, 
3 mm thick, translucent thermoplastic bite splints were 
made in the thermo-vacuum device (Plastvac P7, Bio-
art Dental Equipments, São Paulo, Brazil). The splints 
were fused in the articulator in the preregistered posi-
tion using a micro torch (Piezo Electronic Micro Torch-
GB 2001, Micro Torch-Blazer) (18).
-Sleep bruxism assessment
Along with the valid portable respiratory evaluation, 
patients used a validated against polysomnography dis-
posable and portable EMG device (BiteStrip®) during 
sleep for SB assessment (20). The BiteStrip evaluates 
the number of SB episodes by the registration of the 
left masseter EMG during 5 hours of sleep time. After 
utilization, an electrochemical display shows values be-
tween 0 to 3 (e.g., 0 = no bruxism, ≤ 39 episodes; 1 = 
mild bruxism, 40 - 74 episodes; 2 = moderate bruxism, 
75 - 124 episodes; 3 = severe bruxism, ≥ 125 episodes; 
and E = error message) (21).
-Criteria for temporomandibular disorders assessment
Selected patients underwent the clinical examination for 
assessment of signs and symptoms of TMD with the val-
idated Brazilian Portuguese version of the RDC/TMD 
axes I and II (22). The clinical examination was per-
formed by the same examiner, who did not participate 
in the selection and portable instruments application, 
following the guidelines of the RDC/TMD axis I (http://
www.rdc-tmdinternational.org/TMDAssessmentDi-
agnosis/RDC-TMD/Translations/Portuguese(Brazil).
aspx). The variables analyzed were: a) disability points 
(DP), b) chronic pain grade (CPG), c) characteristic pain 
intensity (CPI), d) muscle disorders (group I), e) disk 
displacement (group II), and f) temporomandibular 
joint arthralgia/osteoarthrosis/osteoarthritis (group III).
-Statistical analysis and sample size calculation
For the statistical analysis, the SPSS v. 20.0 (SPSS, Chi-
cago, Illinois, USA) was used. The Shapiro-Wilk test 
was used for normality testing. Wilcoxon and Paired 
Student’s t tests were used for before-and-after evalua-
tion (p < 0.05). The sample size calculation, comparing 
two proportions (confidence level = 95%, type I error = 
0.05, type II error = 0.2, expected difference between p1 
and p2 = 40%) yielded a sample = 20 (23).
Results
-Social and demographic description of the population
Out of 20 subjects who carried out the first portable 
study, 2 did not perform the second evaluation (i.e., 10% 
drop out rate). One patient did not tolerate the maxil-
lary/mandibular arch alginate impression, and the other 
felt discomfort during the first device. The final sam-
ple (n = 18) was comprised predominantly by children 
(mean age = 8.3±2.3 years, range = 5-12 years), from 
both sexes (55.6% males, 44.4% females), in the elemen-
tary school (66.7%) and pre-school (33.3%) levels, and 
predominantly from low income families with income 
up to 3 minimum wages per month (94.4%).
-Obstructive sleep apnea syndrome evaluation by a por-
table monitoring device
In Table 1, the cardiovascular portable monitoring ex-
amination with the ApneaLinkTM Plus has shown an 
improvement in most variables after the MOA use. The 
median ODI has shown a sharp and significant reduc-
tion (33.3%, p < 0.01). The mean RDI reduced signifi-
cantly in all patients of our sample (55%, p < 0.001). 
The number of snoring events has also declined with 
the treatment (55.5%, p < 0.001). The average oxygen 
saturation also had a significant reduction (p < 0.05). 
The Nadir SpO2 significantly increased in 7.6% after 
the MOA use (p < 0.05). The time with oxygen satura-
tion below 90% (% SpO2 < 90%) and the registration 
time have also declined, but they were non-significant.
-Signs and symptoms of temporomandibular disorders 
and sleep bruxism
In Table 2, the signs and symptoms of TMD did not in-
crease after the use of the MOA. On the contrary, some 
RDC/TMD axis II variables have shown significant re-
duction: chronic pain grade (p <0.01) and characteristic 
pain intensity (p < 0.05). Disability points have shown 
no change, and it was non-significant. In the RDC/TMD 
axis I variables, only muscle disorders were present, 
and they have also shown a tendency towards reduc-
tion (20%), but they were non-significant. Neither disk 
displacements nor TMJ arthralgia/osteoarthritis/osteo-
arthrosis disorders were diagnosed in this sample. Re-
garding the BiteStrip®, a significant and sharp reduc-
tion (66%, p < 0.01) was observed in SB prevalence.
-The subjective sleep quality improvement
The parents’ subjective report on the SDSC demonstrat-
ed a very significant percent reduction/improvement in 
all analyzed variables: a) disorders of initiating and 
maintaining sleep (34.5%, p < 0.001), b) sleep breath-
ing disorders (37.5%, p < 0.001), c) disorders of arousal/
nightmares (16.3%, p < 0.01), d) sleep wake transition 
disorders (32.2%, p < 0.001), e) disorders of excessive 
somnolence (19.9%, p <0.01), and f) sleep hyperhidrosis 
(21.8%, p < 0.01) (Table 3).
Discussion
The MOA has shown here reduced snoring and im-
proved airflow in the treatment of children with OSAS 
in both subjective (i.e., parents’ self-reported SDSC) 
and objective (ApneaLinkTM Plus) assessments. This 
success has already been demonstrated in adults by 
promoting: the reduction in the daytime sleepiness and 
in the obstructive episodes during sleep, the improve-
ment in the oxygen saturation, the reduction in snoring 
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Before (n=18) After (n=18) P value









No change = 4 <0.01*
Respiratory disturbance index (RDI)








No change = 0 <0.001*









No change = 0 <0.001*








No change = 8 NS*(p=0.07)








No change = 5 <0.05*
Nadir SpO2
Mean (± standard deviation) 82.6 (±7.6) 88.9 (±4.4) NC <0.05**
Registration time (minutes)
Mean (± standard deviation) 412.7 (±89.4) 373.8 (±76.6) NC
NS**
(p=0.09)
Table 1. Portable monitoring (ApneaLinkTM Plus, version 9.00, ResMed) before and after the use of a mandibular advancement intraoral appli-
ance (MOA) in children between 5 to 12 years diagnosed with sleep apnea obstructive syndrome (OSAS).
* Wilcoxon signed rank test; ** Paired Student’s t test; 
NS: non-significant; NC: non-computed
intensity and frequency, and the improvement in sleep 
quality (24). In patients with skeletal/occlusal altera-
tions undergoing orthodontic treatment, improvement 
in AHI and facial profile has also been demonstrated 
(25-29). The MOA made here from translucent thermo-
plastic soft bite splints were flexible, unexpensive, com-
fortable, easily adaptable, and used by all subjects; they 
had no interference with dental/skeletal growth within 
the time period (i.e., 60 days) assessed. However, long-
term longitudinal studies should be performed, due to 
possible irreversible changes in the dentition and TMJs 
(29). The durability of these soft appliances is also lim-
ited, so it is a temporary solution (8,19,20).  
Similar to the literature, ApneaLinkTM Plus was an ex-
cellent alternative for childrens’ OSAS diagnoses. Only 
one patient did not tolerate the device, indicating a high 
compliance by children and treatment acceptance. It 
can be indicated for monitoring the treatment response 
with MOA, upper airway surgery, and weight loss (30). 
The OSAS diagnostic improvement after treatment 
with the ApneaLinkTM Plus agreed with the results of 
the SDSC  (Brazilian Portuguese version) answered by 
parents (10,11). The SDSC has also shown improvement 
in respiratory difficulty during sleep, snoring and sleep 
apnea; agreeing with the ApneaLinkTM Plus results. 
However, this cardiovascular monitoring device, dif-
ferent than the overnight in lab PSG, neither assesses 
sleep macrostructure, nor CO2 measurement (14,15). 
On the other hand, the device has the capacity to assess 
air flow, thoracic band, and SpO2 in the patient’s home 
sleep, which is an advantage in pediatric populations 
(15).
The subjective SDSC results have also shown significant 
reduction in grinding sounds after MOA use, agreeing 
with the objective reduction assessed by the BiteStrip® 
of SB events. Similar to the literature, MOA has shown 
significantly greater SB reduction when compared to 
the Michigan-type bite splint (3,7,8,19,20). On the oth-
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Before (n=18) After (n=18) Wilcoxon 
Sign test
P value








No change = 6
<0.01*








No change = 14
NS*








No change = 14
<0.05*



































Table 2. Sleep bruxism assessment (BiteStrip®) and the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) 
axes I and II assessment before and after the use of a mandibular advancement intraoral appliance (MOA) in children between 5 to 12 
years diagnosed with sleep apnea obstructive syndrome (OSAS).
* Wilcoxon sign ranked test; ** McNemar test
NS: non-significant; NC: non-computed
er hand, MOA cannot replace the Michigan-type bite 
splint in patients without OSAS, only in those cases 
where both conditions are in place due to the appli-
ance’s irreversible side effects (20). However, portable 
EMG cannot replace PSG, and new studies confirming 
our findings using PSG must be conducted (19,20). This 
BiteStrip® is indicated for children due to its screen-
ing validity, its non-invasive design , and its comfort. In 
the study sample, muscular and articular disorders (i.e., 
disk displacements and TMJ pain) were not diagnosed 
and were not aggravated after the MOA treatment in the 
short term. In fact, chronic pain grade and characteris-
tic pain intensity had significant reduction. 
Conclusions
Treatment with a soft mandibular advancement intra-
oral appliance has demonstrated in this study to be ef-
fective in the reduction of obstructive sleep apnea and 
sleep bruxism in a pediatric population in most objec-
tive and subjective sleep and sleep bruxism assessments 
performed. No worsening in signs and symptoms of 
temporomandibular disorders has been noted.
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Before (n=18) After (n=18) P value
Disorders of initiating and maintaining sleep
Mean (± standard deviation) 41.1 (±14.7) 26.9 (±8.6) <0.001*
Sleep breathing disorders
Mean (± standard deviation) 46.4 (±11.3) 29.0 (±5.2) <0.001*
Disorders of arousal/nightmares
Mean (± standard deviation) 19.0 (±3.4) 15.9 (±4.8) <0.01*
Sleep wake transition disorders
Mean (± standard deviation) 26.4 (±7.7) 17.9 (±5.7) <0.001*
Disorders of excessive somnolence
Mean (± standard deviation) 27.6 (±9.3) 22.1 (±5.9) <0.01*
Sleep hyperhidrosis
Mean (± standard deviation) 10.1 (±3.8) 7.9 (±1.9) <0.01*
Table 3. Sleep Disturbance Scale for Children (SDSC) assessment before and after the use of an intraoral appliance in children be-
tween 5 to 12 years diagnosed with obstructive sleep apnea syndrome (OSAS).
* Paired Student’s t test
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